Table 1.
Sample size for available DNA and RNA sequencing data in primary tumors and paired control samples
|
Cohort |
Primary tumor |
Matched controls |
||
|---|---|---|---|---|
| |
|
|
Blood |
Solid tissue |
| RNA | DNA | DNA | DNA | |
| AML, acute myeloid leukemia |
123 |
nt |
nt |
nt |
| COAD, colon adenocarcinoma |
194 |
77 |
56 |
16 |
| KIRK, kidney renal clear carcinoma |
132 |
nt |
nt |
nt |
| KIRP, kidney renal papillary cell carcinoma |
15 |
nt |
nt |
nt |
| LUAD, lung adenocarcinoma |
58 |
nt |
nt |
nt |
| LUSK, lung squamous cell carcinoma |
151 |
nt |
nt |
nt |
| READ, rectum adenocarcinoma |
71 |
40 |
35 |
4 |
| STAD, stomach adenocarcinoma |
57 |
3 |
0 |
2 |
| UCEC, uterine corpus endometrioid carcinoma | 157 | nt | nt | nt |
Control samples were derived from either whole blood or adjacent normal tissue (not both) from the same patient. nt, not tested.